LAB
Standard BioTools, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.62
+0.85%Year over year
Reported trailing growth
- Revenue
- -22.0%
- EBITDA
- +12.0%
- EBIT
- +26.6%
- EPS
- +67.7%
- Free cash flow
- +33.3%
- Operating cash flow
- +26.3%
Forward estimates
Based on analyst estimates
- Revenue
- -2.6%
- EBITDA
- +29.8%
- EPS
- -45.6%
Three-year CAGR
- Revenue
- -4.5%
- EBITDA
- +27.5%
- EBIT
- +46.8%
- Net income
- +46.1%
- EPS
- +61.5%
- Free cash flow
- +45.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026